Navigation Links
SIRION Biotech to Present at April 2020 Virtual Investor Summit: Company to present update on support of its COVID-19 project using its viral vector platforms
Date:4/18/2020

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene and cell therapy, today announced it will present a company update on its work expediting gene therapy research and advancing drug development during the April 2020 Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the Company’s Chief Operating Officer, will also provide an update on SIRION’s new initiative to support COVID-19 research. The presentation will take place on Thursday, April 23 at 10:30 a.m. EDT followed by a live Q&A session with registered investors and other conference attendees.

A live webcast of the presentation will be available here. Following the conference, an archived version of the webcast will be available on the company’s website.

Presentation Details
Date: Thursday, April 23, 2020
Time: 10:30 a.m. EDT
Webcast link: https://bit.ly/34GtQjT

About the Virtual Investor Summit
The April 2020 Virtual Investor Summit will take place on April 22nd and 23rd from 10:00am – 3:00pm EDT. The event will feature presentations from public and private companies in multiple industries including life sciences/biotech, infrastructure and transportation. Management teams will present a live audio webcast accompanied by a slide presentation and be available to participate in virtual Q&A sessions immediately following their presentation. Investors, media and interested parties can access the event schedule and individual company webcast details at the event website, virtualinvestorsummit.com.

About SIRION Biotech GmbH
SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST™ has been used in several clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
lingelbach@sirion-biotech.com

Media and Investor Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com

Read the full story at https://www.prweb.com/releases/sirion_biotech_to_present_at_april_2020_virtual_investor_summit_company_to_present_update_on_support_of_its_covid_19_project_using_its_viral_vector_platforms/prweb17057548.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. COVID-19 Stimulus Grants for Biotech Research Companies Offered by InstantGMP
2. ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
3. Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra
4. Panitch Schwarze Adds Biotechnology and Life Science Experts to IP team
5. GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells
6. GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells
7. Lifecycle Biotechnologies Introduces High Purity Powder Chemicals Capabilities
8. Lifecycle Biotechnologies Releases 2020 Company Prospectus
9. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
10. Intelligent.com Announces Best Master's in Biotechnology Degree Programs for 2020
11. Biopharma Leaders to Discuss and Share Insights on the Regional Biopharma Ecosystem at LeadingBiotech’s NY/NJ CEO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to ... Roche and J&J have annual Research and Development spending in excess of US ...
(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has ... be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar ... switches in a push-pull configuration; yielding fast fall time for a capacitive load. ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now ... up to 200 million stem cells. Depending on the patient's condition, treatment may be ... US will die having some form of Alzheimers dementia, and the incidence continues to ...
Breaking Biology Technology: